Showing 1331-1340 of 2150 results for "".
- Schwind Receives CE Mark Approval for the Schwind ATOS Femtosecondhttps://modernod.com/news/schwind-receives-ce-mark-approval-for-the-schwind-atos-femtosecond/2478006/Schwind eye-tech-solutions announced that it has received CE Mark approval for the Schwind ATOS femtosecond laser. This enables refractive surgeons to offer their patients SmartSight, the latest generation of lenticul
- OD-OD Introduces a New Learning App for Retinal Laser Treatmenthttps://modernod.com/news/od-od-introduces-a-new-learning-app-for-retinal-laser-treatment/2479529/To address growing demand for interactive learning technology, OD-OS has developed a tool for implementing a better approach to retinal laser treatment: The Navigate App. Navigate is a free, interactive tool designed to support residents and team education—both onsite and online. The platf
- CE-Mark Granted to deepeye Medical for AI Tool for Retinal Therapy Planninghttps://modernod.com/news/ce-mark-granted-to-deepeye-medical-for-ai-tool-for-retinal-therapy-planning/2482816/deepeye Medical has received CE Mark for its deepeye TPS¹ (Therapy Planning Support) platform. The Class IIa approval was made under the EU Medical Device Regulation (MDR 2017/745), following certification by the Notified Body
- Nordic Pharma Receieves CE Mark Approval for Lacrifill Canalicular Gelhttps://modernod.com/news/nordic-pharma-receieves-ce-mark-approval-for-lacrifill-canalicular-gel/2482729/Nordic Group, the parent company of Nordic Pharma, announced that its dry eye therapy Lacrifill has received CE mark approval. This regulatory milestone, which Nordic says was achieved several months ahead of schedule, allows Nordic Pharma to introduce Lacrifill across Europea
- VisionGift Announces the Retirement of Longtime Medical Director, Mark Terry, MDhttps://modernod.com/news/visiongift-announces-the-retirement-of-longtime-medical-director-mark-terry-md/2482595/VisionGift, a nonprofit dedicated ot ocular donation and corneal transplantation, announced the retirement of its medical director Mark Terry, MD, after 34 years of dedicated service to the field of eye banking. Succeeding him in this role will be Winston Chamberlain, MD, PhD, and
- Ophtec Receives CE Mark Approval for Artiplus Phakic IOL for Presbyopiahttps://modernod.com/news/ophtec-receives-ce-mark-approval-for-artiplus-phakic-iol-for-presbyopia/2482548/Ophtec announced it has received CE Mark approval for its Artiplus Phakic IOL, which is designed for young presbyopes, typically in their early 40s. The Artiplus lens is designed to provide clear vision at all distances, eliminating the need for reading glasses or other corrective
- Nidek Receives CE Mark Approval for Preloaded IOL Injection Systemhttps://modernod.com/news/nidek-receives-ce-mark-approval-for-preloaded-iol-injection-system/2482315/Nidek has received CE Mark for the NP-1/NP-1C Preloaded IOL Injection System, a fully preloaded injection system with an aspheric hydrophobic soft acrylic lens designed for smoother, safer, and secure IOL implantation. The NP-1/NP-1C injector is developed for smooth, controlle
- Dopavision Appoints Mark S. Wuttke, PhD, as Chief Executive Officerhttps://modernod.com/news/dopavision-appoints-mark-s-wuttke-phd-as-chief-executive-officer/2480881/Dopavision announced that Mark S. Wuttke, PhD, has been appointed as the company´s Chief Executive Officer. He succeeds Dopavision´s co-founder and previous Managing Director Stefan Zundel, who will remain on Dopavision´s advisory board and continue to advise the company.</
- Implandata’s Receives CE Mark for the EYEMATE-SC Biosensor for Remote Glaucoma Carehttps://modernod.com/news/implandatas-receives-ce-mark-for-the-eyemate-sc-biosensor-for-remote-glaucoma-care/2479310/Implandata Ophthalmic Products announced that its EYEMATE-SC biosensor has obtained CE Mark. This device is used in conjunction with the EYEMATE system for digitally enabled remote glaucoma monitoring and management. The patented EYEMATE system is the world’s only clinically-validated pro
- Aura Biosciences Names Mark De Rosch, PhD, Chief Operating Officerhttps://modernod.com/news/aura-biosciences-names-mark-de-rosch-phd-chief-operating-officer/2479008/Aura Biosciences announced the appointment of Mark De Rosch, PhD, as Chief Operating Officer. In his role, he will be responsible for leading Aura’s global operations and regulatory strategy. Dr. De Rosch brings to Aura more than 30 years of experience in leading global regulatory and deve